$1.94
3.19% yesterday
Nasdaq, Nov 25, 10:15 pm CET
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Sangamo Therapeutics, Inc. Stock price

$1.94
+0.44 29.33% 1M
+1.34 225.94% 6M
+1.40 257.08% YTD
+1.57 419.41% 1Y
-7.00 78.30% 3Y
-8.41 81.26% 5Y
-10.12 83.91% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.06 3.19%
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Key metrics

Market capitalization $404.78m
Enterprise Value $393.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.52
P/S ratio (TTM) P/S ratio 7.74
P/B ratio (TTM) P/B ratio 10.34
Revenue growth (TTM) Revenue growth -74.04%
Revenue (TTM) Revenue $52.29m
EBIT (operating result TTM) EBIT $-134.22m
Free Cash Flow (TTM) Free Cash Flow $-117.11m
Cash position $39.20m
EPS (TTM) EPS $-0.75
P/E forward negative
P/S forward 6.69
EV/Sales forward 6.50
Short interest 9.17%
Show more

Is Sangamo Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Sangamo Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

Buy
57%
Hold
43%

Financial data from Sangamo Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
52 52
74% 74%
100%
- Direct Costs 10 10
50% 50%
20%
42 42
77% 77%
80%
- Selling and Administrative Expenses 23 23
18% 18%
43%
- Research and Development Expense 143 143
42% 42%
274%
-124 -124
43% 43%
-237%
- Depreciation and Amortization 10 10
50% 50%
20%
EBIT (Operating Income) EBIT -134 -134
25% 25%
-257%
Net Profit -136 -136
45% 45%
-260%

In millions USD.

Don't miss a Thing! We will send you all news about Sangamo Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sangamo Therapeutics, Inc. Stock News

Neutral
Business Wire
7 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.
Neutral
Seeking Alpha
13 days ago
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
14 days ago
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results.
More Sangamo Therapeutics, Inc. News

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Head office United States
CEO Alexander Macrae
Employees 405
Founded 1995
Website www.sangamo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today